- Researchers at Aethlon Medical (NASDAQ:AEMD +3.4%) have demonstrated the ability of the Hemopurifier device to remove viral pathogens from blood samples obtained from organ transplant patients who were suffering from sepsis.
- Results showed that the Hemopurifier was able to reduce the level of Herpes Simplex virus 1 (HSV1) by 72% after six hours. Levels of Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) were reduced 77% and 88%, respectively.
-
Hemopurifier is a bio-filtration device designed to remove bioterror-related pathogens. Studies have also shown its ability to remove the Zika virus from serum.